Results: Mean prosthesis diameter was 22.2 AE 0.9 mm for FS and 22.4 AE 1.0 mm for TAVR. In-hospital mortality was 2.1% for FS and 6.3% for TAVR (P ¼ .02). Postoperative FS peak gradients were 19.1 AE 9.6 mm Hg (mean 10.8 AE 5.9 mm Hg); TAVR peak gradients were 20.2 AE 9.5 mm Hg (mean 10.7 AE 6.9 mm Hg) P ¼ .57 (P ¼ .88). Postoperative effective orifice area was 1.93 AE 0.52 cm 2 for FS and 1.83 AE 0.3 cm 2 for TAVR (P ¼ .65). There was no prostheses-patient mismatch in either group. Postoperative grade 2-3 paravalvular leak was present in 3.5% for TAVR and 0.7% for FS. Postoperative permanent pacemaker implant rate was 12% for TAVR and only 1 case (0.7%) in the FS group (P <.001).
The Freedom SOLO pericardial stentless valve.
Central Message
In patients with small aortic annuli and intermediate risk, Freedom SOLO stentless valve shows excellent hemodynamics, similar to transcatheter aortic valve replacement, with better outcomes.
Perspective
The use of transcatheter aortic valve replacement negatively affects the perioperative outcome with significantly greater early mortality, greater incidence of periprosthetic regurgitation and postprocedural atrioventricular block requiring pacemaker implant. Further studies are warranted to validate transcatheter aortic valve replacement indications in patients with intermediate-low risk profile and small aortic annulus.
See Editorial Commentary page 559.
The recently published Placement of Aortic Transcatheter Valves (PARTNER) 2 Trial 1 concluded that clinical outcomes for transcatheter aortic valve replacement (TAVR) were similar to surgical aortic valve replacement (sAVR) with respect to the primary end point of death or disabling stroke in patients with an intermediate-risk profile. Despite the findings of this landmark prospective randomized trial, however, this study included a heterogeneous population of patients in the surgical group, particularly in regard to the type of surgical prosthesis used and procedures.
Furthermore, the hemodynamic performance of stented valves could lead to a greater likelihood of patientprosthesis mismatch (PPM), thus leading to a potential overestimation of the hemodynamic advantages of TAVR in this specific subset of patients. In patients with small aortic annulus, for example, a greater incidence of PPM associated with greater early and late mortality has been reported, mainly when ventricular function is reduced. [2] [3] [4] In such cases stentless prostheses provide excellent hemodynamic results compared with stented prostheses, [5] [6] [7] possibly with improved long-term durability and reduced long-term mortality rates. 8 The routine use of stentless bioprostheses for sAVR, however, is still limited, despite the well-known superior hemodynamic performances compared with stented bioprostheses, 2, 9, 10 which continues to be the gold standard treatment in low-and intermediate-risk aortic stenosis patients older than 65 years of age.
During the past decade, the use of TAVR in patients with severe aortic stenosis and high operative risk has been shown to be a reasonable alternative to conventional sAVR in patients with prohibitive surgical risk. 11, 12 Nevertheless, an ongoing debate continues regarding the best operative strategy for intermediate-risk patients for whom sAVR demonstrates superior results compared with TAVR in terms of postoperative morbidity and mortality. 13, 14 Since their introduction into clinical practice, concerns exist regarding TAVR performance due to a ''left-in-place'' calcified native valve; however, recent studies have demonstrated low transprosthetic gradients at early and mid-term, even in patients with small aortic annuli. 15 Given the favorable hemodynamic performance of stentless valves and the paucity of data comparing such prostheses with transcatheter valves, we sought to investigate the performance and clinical outcomes of stentless sAVR versus TAVR in a population of patients with isolated, severe aortic valve stenosis and an intermediate-risk profile.
METHODS

Study Population
The present study was an observational, retrospective, multicenter cohort study in 795 consecutive patients with isolated severe aortic valve stenosis and an intermediate-risk profile (Society of Thoracic Surgeons [STS] Predictive of Mortality 4%-10%) 16, 17 undergoing sAVR or TAVR after multidisciplinary Heart Team evaluation. Data were collected from 7 European cardiac centers, including data for demographic characteristics, comorbidities, and comprehensive information regarding the type of intervention. All centers were selected according to their high-volume activity either in stentless valve surgery and TAVR procedures. The institutional review board of the University of Brescia approved this retrospective analysis of clinically acquired data, and informed consent for anonymous data treatment for scientific purposes was obtained.
From May 2010 to December 2014, 795 patients with isolated severe aortic valve stenosis and an intermediate-risk profile with aortic annulus 23 mm, underwent aortic valve replacement (AVR); 420 patients underwent sAVR with the bovine pericardial stentless bioprosthesis Freedom SOLO (FS) valve (Sorin Group, Milan, Italy; Figure 1 ), whereas 375 patients were treated by TAVR. Preoperative patient characteristics are listed in Table 1 . A propensity score matching analysis was performed to reduce selection bias. Following 1:1 propensity-score matching, 142 patients from each treatment group were selected to obtain 2 homogeneous populations (Table 2) . Transthoracic echocardiographic baseline assessment was performed in every patient (Table 3) . Transesophageal echocardiography or stress echocardiography was performed only in cases of low-flow stenosis that required further evaluations. Predischarge transthoracic echocardiography was performed in every patient (Table 3) . 
Abbreviations and Acronyms
The approach of sAVR versus TAVR was adopted after a multidisciplinary evaluation including preoperative risk assessment (STS score) and additional findings such as frailty, anatomy, and peripheral atherosclerotic disease.
Surgical Technique FS valve implantation. The characteristics of the FS valve have been reported previously. 18 FS is manufactured from 2 bovine pericardial sheets without a sewing ring stent. Its unique design allows for efficient implantation in a supra-annular position with a running suture. The operative approach was via full midline sternotomy (74%) or by upper ''J-shaped'' mini-sternotomy as a minimally invasive approach (26%). Myocardial protection was achieved with cold crystalloid or blood cardioplegia delivered antegrade or retrograde. Transverse aortotomy was performed approximately 1 cm above the sinotubular junction, and the aortic valve was excised with debridement of the annulus. Valve size selection was made corresponding to the sizer that comfortably passed through the annulus. Valve implantation was performed, in a supra-annular subcoronary position with three 4-0 polypropylene sutures constructed as a single continuous suture line (Video 1). 18 After the patient was weaned from cardiopulmonary bypass, transoesophageal echocardiography was performed to assess valve function. After valve deployment, the presence and severity of aortic regurgitation was assessed visually by determination of the relative amount of radiographic contrast medium in the ventricle after injection into the proximal aorta and classified using a scale of 0 to 4. Balloon dilatation was performed in cases of significant paravalvular leak (PVL), defined as PVL of grade 2 or greater and then reassessed with contrast injection and transesophageal echocardiography.
TAVR Procedure
Endpoints of the study. Primary endpoints were 30-day mortality (valve-and cardiac-related mortality) and hemodynamic performance: peak and mean gradients, effective orifice area, severe PPM (indexed effective orifice area < 0.65 cm 2 /m 2 ), 19 and PVL ! grade II. Secondary endpoints included the incidence of perioperative complications such as myocardial infarction, cerebrovascular accidents and major hemorrhagic events, atrioventricular blocks requiring pacemaker (PM) implantation, acute kidney failure, and respiratory complications, according to Valve Academic Research Consortium 2 Criteria. Kaplan-Meier analysis. A P value less than .05 was considered significant. A binary logistic regression model was used to develop a propensity score for each patient. The variables included in the propensity score model were age, STS score, body mass index, female sex, hypertension, dyslipidemia, chronic obstructive pulmonary disease, previous percutaneous coronary intervention, previous myocardial infarction, coronary artery disease, cerebrovascular accident, peripheral arterial disease, diabetes, New York Heart Association III-IV, chronic renal insufficiency, reoperation, and ejection fraction. We derived propensity scores including pretreatment variables that were associated at P < .10 in a multivariable model. Nearestneighbor propensity score matching subsequently was used to match 1:1 patients 20 in the sAVR group and TAVR group. Matching was performed using calipers of width of 0.2 of the standard deviation of the logit of propensity score. Hosmer-Lemeshow test was performed to assess the goodness-of-fit of propensity-match model (P ¼ .204). The propensity scores distribution after matching was assessed graphically with histograms ( Figure 2 ). As described in recent JTCVS statistical commentaries, the matched standardized differences of each covariate were less than 10%, thus proofing the comparability between the 2 groups ( Figure E1 ). 21, 22 We performed a stabilized inverse probability weighting analysis on the entire cohort as a sensitivity analysis 23 to confirm the robustness of results obtained (Table E1) .
Univariate and multivariate logistic regression analysis was performed to identify independent predictors of mortality among preoperative characteristics identified from propensity score model associated to the dependent variable (Table 4) . Outcomes were adjusted for site performing a regression model with a backward logistic strategy with a removal P value < .20. Characteristics of unmatched patients and their outcomes were reported as Tables E2 to E4. The statistical package used was SPSS software (Version 23; IBM Corp, New York, NY).
RESULTS
Preoperative Characteristics
Baseline characteristics of patients who underwent sAVR with FS valve (n ¼ 420) and TAVR (n ¼ 375) are listed in Table 1 . Patients undergoing TAVR were older compared with those receiving FS implantation (FS group: 75 AE 8.2 years vs TAVR: 79 AE 6.8 years; P ¼ .007) and the STS score was significantly greater in patients undergoing TAVR (FS group: 6.8% AE 4.2% vs TAVR: 9.9% AE 3.2%; P ¼ .009) before matching. No differences were reported concerning aortic valve area (planimetric and indexed), and transvalvular peak/mean gradients. Frailty assessment was defined as ''5-meter walk test time >7 seconds,'' and its incidence was similar before (23.3% SOLO vs 27.2% TAVR P ¼ .190) and after matching (24.6% SOLO vs 25.3% TAVR P ¼ .892).
Operative Results
Operative results are listed in Table 3 . Of note only a single patient had an emergency procedure in the sAVR group (0.7%) for active infectious endocarditis with acute heart failure unresponsive to medical therapy. Five patients (3.5%) in the TAVR group had an emergency procedure, 3 patients for acute heart failure requiring intra-aortic balloon pump support and 2 patients for cardiac arrest 
Postoperative Complications
Before and after propensity matching, 30-day mortality rate was greater in the TAVR group (mortality prematch:
2.8% FS group vs 7.5% TAVR group, P ¼ .003; mortality postmatch: 2.1% vs 6.3%, P ¼ .021). In the prematch series, valve-related death and cardiac death were greater in the TAVR group; after matching they remained greater, although this was not statistically significant (Table 5) . No valve-related death was reported at 30 days in FS group, whereas 7 patients had a valve-related death in the TAVR group (P ¼ .005), in 4 cases as the result of valve malpositioning and embolization requiring emergency cardiac surgery and in 3 cases as the result of annular rupture with fatal bleeding. In the TAVR group, there was also a grater incidence of acute kidney injury (2.6% in FS group vs 6.1% in TAVR group, P ¼ .025 postmatch) and continuous venovenous hemofiltration (2.1 vs 3.2 respectively, P ¼ .069 postmatch).
PM implantation was greater in the TAVR group both in prematch and postmatch series (12% vs 0.7%, P < .001 postmatch). No peripheral vascular complications were reported in the sAVR group, whereas 10 patients had major vascular complications in the TAVR group (P ¼ .002 postmatch). A greater incidence of postprocedural cerebrovascular accident was reported in the TAVR group, although not statistically significant (2.8% vs 1.4%, P ¼ .684 postmatch). Univariate and multivariate regression analyses (Table E1 ).
Postoperative Echocardiographic Evaluation
The Doppler echocardiographic data at hospital discharge are listed in Table 3 . Predischarge transthoracic echocardiography has been performed routinely in every patient (1.6% missing data).
The peak and mean transprosthetic gradients were similar at discharge in the TAVR group compared with the sAVR group (P ¼ .572 and P ¼ .884, respectively), as were the aortic valve area and aortic valve area index (P ¼ .651 and P ¼ .738, respectively). There was no severe PPM in either group. At least moderate aortic regurgitation was present in 3.5% of the TAVR patients compared with 0.7% of the sAVR patients after the procedure (P ¼ .534). Aortic regurgitation was paravalvular in all the cases in the TAVR group.
DISCUSSION
The present study analyzed hemodynamic performances and postoperative complications of sAVR with FS stentless valve compared with TAVR in intermediate-risk patients with aortic stenosis and a preoperative echocardiographic annulus measurement 23 mm.
In our series, 30-day mortality after TAVR was similar to several published papers, 14, 24 whereas surgical results were better than previous reports in this specific subset of patients. 15, 25, 26 The suggested benefit of surgical AVR on mortality in our study seems to be in contrast with the PARTNER 2 data; we found lower surgical mortality (2.8% vs 4.1%) whereas the TAVR mortality was substantially greater (7.5% vs 3.9%) than in PARTNER 2. Such a discrepancy is probably the result of multiple factors. The unique design characteristics of the FS allow suprannular implantion, reducing the risk of atrioventricular block and concomitant unplanned procedures including aortic root enlargement or replacement, as reported in PARTNER 2. 1 In our study, the TAVR group included both balloon and self-expandable prostheses; furthermore, given the small annular size, this population would be predicted to be at greater risk for coronary ostia occlusion and annular rupture and the choice of the device might have impacted clinical outcomes. In addition, only isolated AVR have been included in our series, thus reducing potential perioperative complications occurring in the surgical group. Of note, other authors 13 also observed a lower surgical mortality in intermediate risk patients than that reported in the PARTNER 2 trial. A greater prevalence of concomitant or unplanned procedures in the surgical cohort of the PARTNER 2 trial where concomitant CABG was required in 14.5% of patients undergoing sAVR whereas concomitant percutaneous coronary intervention was performed only in 3.9% of the TAVR group. 1 Similarly, the greater incidence of permanent PM implantation, PVL, and acute kidney injury in the TAVR group may have been related to the earlier generation technology.
In our study, no severe PPM was observed, and hemodynamic performance was similar in both groups compared with previous publications 26 reporting better immediate results in the TAVR group with comparable results to stentless prostheses reported 3 months after discharge. In particular, although stentless valves offer good hemodynamic outcomes and reduced incidence of PPM, superior outcomes in intermediate risk patients, compared with stented valves, has never been demonstrated, possibly owing to the complexity of stentless implantation and the associated prolonged crossclamp times with previously used stentless valves, which may have negatively biased results. Furthermore, the hemodynamic superiority of stentless aortic bioprostheses is still debated, with available studies reporting conflicting data 27-29 on PPM incidence in small annuli between 17% and 58%. 25 These opposing views also may be related to the different type of stentless prostheses used in various studies, as well as variability in implant techniques (single suture vs subcoronary double suture vs full root implantion). Several studies report that the use of transcatheter valves in this particular subset of patients provides excellent hemodynamic and procedural results, 15, 25, 26 albeit a comparison with the FS pericardial stentless bioprosthesis, implanted with a single supra-annular suture technique, has not been performed previously.
Our experience showed that neither cross-clamp time nor periprocedural complications 30 were increased in our FS cohort compared with conventional prostheses without a downside to surgical complexity, which may be attributable to the unique and relatively simple implantation technique afforded by FS, while providing the excellent hemodynamic performance expected of a stentless valve. Moreover, we found out that in intermediate-risk patients 30-day mortality was greater in the TAVR cohort compared with FS, with similar hemodynamic performance in the 2 groups. Given the propensity-matched nature of the study that reduces, selection bias, this greater 30-day mortality of nearly 4 times our surgical cohort seems to be related to the TAVR procedure itself. TAVR prostheses are designed to be deployed in a smaller aortic annulus than the prosthesis, which, because the elastic characteristics of the annulus, can allow moderate prosthesis oversizing. Although this ''controlled oversizing'' assures the best valve anchoring and fitting in the native annulus, any excessive oversizing may lead to catastrophic postprocedural complications such as annular rupture or more commonly, to atrioventricular conduction disturbances. Moreover, for transcatheter prostheses, oversizing is crucial to prevent significant PVL associated with poor early and late outcomes. 31, 32 The incidence of PVL in the TAVR cohort was lower than reported in the PARTNER trial (3.5% vs 12%) 11 and consistent with other series. 1, 25, 33 The reduced incidence of PVL in smaller aortic annuli suggests that such anatomy may allow for a more appropriate expansion and sealing of the transcatheter valve prostheses within the aortic annulus, albeit with a greater risk of a life-threatening annular rupture.
TAVR is associated with an elevated incidence of atrioventricular block requiring permanent PM implantation, [12] [13] [14] due to compression of the cardiac conduction system, which is mostly absent in the FS group because of implantation via a supra-annular subcoronary suture line, 2 at some distance from the conduction pathway. Finally, despite the possibility of renal injury caused by cardiopulmonary bypass, the incidence of postoperative renal failure was significantly lower in the FS cohort, suggesting use of iodinated contrast medium and possible embolic events during the TAVR procedure as more important determinants of postprocedure renal dysfunction.
Limitations of the Study
The main limitation of the study is represented by its retrospective design without prospective randomization responsible for the selection bias in treatment choice. Given the unlikelihood of a randomized trial ever comparing these 2 groups of patients, a propensity-matched comparison reducing, albeit not eliminating, the selection bias in retrospective series, seems to be the most appropriate study design. Because there were no strict and similar criteria for definition of frailty among the participating centers, we decided not to include it in our propensity match model. However frailty, defined as ''5 meter walk test time >7 seconds,'' had a similar and equally distributed incidence in the pre-and postmatching groups.
Of note, every TAVR procedure was performed after multidisciplinary (heart team) evaluation. Despite some selection bias that may have been introduced by arbitrary selection regarding the choice of treatment, this study represents a consecutive series of all patients undergoing AVR directed by a multidisciplinary heart team that hopefully mitigates selection bias in patient enrollment while presenting an important ''real-world'' series of patients.
Site and operator variability should be considered in predischarge transthoracic echocardiographic data evaluation. The impact of missing data has been deemed as minimum, given the observed number of missing data (1.6% of total number of postprocedure echo data) and the plausible assumptions of an underneath missing at random mechanism.
CONCLUSIONS
In patients with small aortic annulus and intermediaterisk profile, both FS and TAVR demonstrated similar excellent hemodynamic performances. Nevertheless, TAVR approach seems to influence, considering all the limitations, the perioperative outcome with significant greater early mortality, greater incidence of prosthetic regurgitation and atrioventricular blocks requiring PM implantation, and a trend through greater PVL rate. Concerning TAVI, we just have been proctored in the first cases by, let's say, expert proctors, so I do not think that the results are influenced by this bias.
About your observation for the STS evaluation, you are probably right. Every surgeon knows very well that concerns about frailty or obesity or other parameters not included in the STS score are really debatable in patients' selection, but this is real-world, multicenter clinical study, and it is very difficult to use same assessment tools in different centers.
And the third one was? Dr Bhama. Just regarding whether had you controlled for frailty do you think the result would have been the same?
Dr Repossini. We always include frailty and obesity in patients' evaluation without objectivating with scores. Anyhow, I don't think we would have had a significant variation.
FIGURE E1. Standardized differences distribution before and after matching. 
